Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 286

1.

The positive predictive value of spontaneous subarachnoid hemorrhage diagnoses in the Danish National Patient Register.

Sonne A, Andersen JB, Rasmussen LS.

Clin Epidemiol. 2019 May 1;11:323-331. doi: 10.2147/CLEP.S197251. eCollection 2019.

2.

Cholangiocarcinoma: State-of-the-art knowledge and challenges.

Banales JM, Cardinale V, Macias RIR, Andersen JB, Braconi C, Carpino G, Alvaro D, Calvisi DF.

Liver Int. 2019 May;39 Suppl 1:5-6. doi: 10.1111/liv.14101. No abstract available.

PMID:
31111668
3.

Causes of hOCT1-Dependent Cholangiocarcinoma Resistance to Sorafenib and Sensitization by Tumor-Selective Gene Therapy.

Lozano E, Macias RIR, Monte MJ, Asensio M, Del Carmen S, Sanchez-Vicente L, Alonso-Peña M, Al-Abdulla R, Munoz-Garrido P, Satriano L, O'Rourke CJ, Banales JM, Avila MA, Martinez-Chantar ML, Andersen JB, Briz O, Marin JJG.

Hepatology. 2019 Apr 10. doi: 10.1002/hep.30656. [Epub ahead of print]

PMID:
30972782
4.

Molecular perturbations in cholangiocarcinoma: Is it time for precision medicine?

Braconi C, Roessler S, Kruk B, Lammert F, Krawczyk M, Andersen JB.

Liver Int. 2019 May;39 Suppl 1:32-42. doi: 10.1111/liv.14085. Epub 2019 Mar 24. Review.

PMID:
30829432
5.
6.

High levels of cAMP inhibit Pseudomonas aeruginosa biofilm formation through reduction of the c-di-GMP content.

Almblad H, Rybtke M, Hendiani S, Andersen JB, Givskov M, Tolker-Nielsen T.

Microbiology. 2019 Mar;165(3):324-333. doi: 10.1099/mic.0.000772. Epub 2019 Jan 21.

PMID:
30663958
7.

Epigenetic events involved in organic cation transporter 1-dependent impaired response of hepatocellular carcinoma to sorafenib.

Al-Abdulla R, Lozano E, Macias RIR, Monte MJ, Briz O, O'Rourke CJ, Serrano MA, Banales JM, Avila MA, Martinez-Chantar ML, Geier A, Andersen JB, Marin JJG.

Br J Pharmacol. 2019 Mar;176(6):787-800. doi: 10.1111/bph.14563. Epub 2019 Feb 11.

PMID:
30592786
8.

Pregnancy Outcomes in Men and Women Treated With Teriflunomide. A Population-Based Nationwide Danish Register Study.

Andersen JB, Moberg JY, Spelman T, Magyari M.

Front Immunol. 2018 Nov 23;9:2706. doi: 10.3389/fimmu.2018.02706. eCollection 2018.

9.

Application of patient-derived liver cancer cells for phenotypic characterization and therapeutic target identification.

Castven D, Becker D, Czauderna C, Wilhelm D, Andersen JB, Strand S, Hartmann M, Heilmann-Heimbach S, Roth W, Hartmann N, Straub BK, Mahn FL, Franck S, Pereira S, Haupts A, Vogel A, Wörns MA, Weinmann A, Heinrich S, Lang H, Thorgeirsson SS, Galle PR, Marquardt JU.

Int J Cancer. 2019 Jun 1;144(11):2782-2794. doi: 10.1002/ijc.32026. Epub 2018 Dec 14.

PMID:
30485423
10.

A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily.

Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Manyam G, Rao A, Shelley S, Liu Y, Ju Z, Hansel D, de Velasco G, Pennathur A, Andersen JB, O'Rourke CJ, Ohshiro K, Jogunoori W, Nguyen BN, Li S, Osmanbeyoglu HU, Ajani JA, Mani SA, Houseman A, Wiznerowicz M, Chen J, Gu S, Ma W, Zhang J, Tong P, Cherniack AD, Deng C, Resar L; Cancer Genome Atlas Research Network, Weinstein JN, Mishra L, Akbani R.

Cell Syst. 2018 Oct 24;7(4):422-437.e7. doi: 10.1016/j.cels.2018.08.010. Epub 2018 Sep 26.

11.

Mental health among children of mothers with multiple sclerosis: A Danish cohort and register-based study.

Andersen JB, Moberg JY, Niclasen J, Laursen B, Magyari M.

Brain Behav. 2018 Oct;8(10):e01098. doi: 10.1002/brb3.1098. Epub 2018 Sep 21.

12.

RNAi screening of subtracted transcriptomes reveals tumor suppression by taurine-activated GABAA receptors involved in volume regulation.

Wielders CLC, van Nierop P, Vormer TL, Foijer F, Verheij J, Lodder JC, Andersen JB, Mansvelder HD, Te Riele H.

PLoS One. 2018 May 22;13(5):e0196979. doi: 10.1371/journal.pone.0196979. eCollection 2018.

13.

IUGR decreases cardiomyocyte endowment and alters cardiac metabolism in a sex- and cause-of-IUGR-specific manner.

Botting KJ, Loke XY, Zhang S, Andersen JB, Nyengaard JR, Morrison JL.

Am J Physiol Regul Integr Comp Physiol. 2018 Jul 1;315(1):R48-R67. doi: 10.1152/ajpregu.00180.2017. Epub 2018 Mar 21.

PMID:
29561647
14.

Does heterogeneity matter in the estimation of tumour budding and tumour stroma ratio in colon cancer?

Eriksen AC, Andersen JB, Lindebjerg J, dePont Christensen R, Hansen TF, Kjær-Frifeldt S, Sørensen FB.

Diagn Pathol. 2018 Mar 20;13(1):20. doi: 10.1186/s13000-018-0697-9.

15.

Single cell profiling reveals window for immunotherapy in liver cancers.

Andersen JB.

Hepatobiliary Surg Nutr. 2018 Feb;7(1):48-51. doi: 10.21037/hbsn.2017.12.04. No abstract available.

16.

Desmoplastic Tumor Microenvironment and Immunotherapy in Cholangiocarcinoma.

Høgdall D, Lewinska M, Andersen JB.

Trends Cancer. 2018 Mar;4(3):239-255. doi: 10.1016/j.trecan.2018.01.007. Epub 2018 Feb 21. Review.

PMID:
29506673
17.

Correction: Breaking up Prolonged Sitting does not Alter Postprandial Glycemia in Young, Normal-Weight Men and Women.

Hansen RK, Andersen JB, Vinther AS, Pielmeier U, Larsen RG.

Int J Sports Med. 2016 Dec;37(14):e4. doi: 10.1055/s-0038-1629925. Epub 2018 Jan 23. German. No abstract available.

PMID:
29361638
18.

Hybrid PET/MRI imaging in healthy unsedated newborn infants with quantitative rCBF measurements using 15O-water PET.

Andersen JB, Lindberg U, Olesen OV, Benoit D, Ladefoged CN, Larsson HB, Højgaard L, Greisen G, Law I.

J Cereb Blood Flow Metab. 2019 May;39(5):782-793. doi: 10.1177/0271678X17751835. Epub 2018 Jan 15.

19.

Genomic perturbations reveal distinct regulatory networks in intrahepatic cholangiocarcinoma.

Nepal C, O'Rourke CJ, Oliveira DVNP, Taranta A, Shema S, Gautam P, Calderaro J, Barbour A, Raggi C, Wennerberg K, Wang XW, Lautem A, Roberts LR, Andersen JB.

Hepatology. 2018 Sep;68(3):949-963. doi: 10.1002/hep.29764. Epub 2018 Jun 12.

PMID:
29278425
20.

Dysregulation of Iron Metabolism in Cholangiocarcinoma Stem-like Cells.

Raggi C, Gammella E, Correnti M, Buratti P, Forti E, Andersen JB, Alpini G, Glaser S, Alvaro D, Invernizzi P, Cairo G, Recalcati S.

Sci Rep. 2017 Dec 15;7(1):17667. doi: 10.1038/s41598-017-17804-1.

21.

Reply.

Koshiol J, Andersen JB, Ferreccio C.

Gastroenterology. 2018 Jan;154(1):260-261. doi: 10.1053/j.gastro.2017.11.026. Epub 2017 Nov 24. No abstract available.

PMID:
29178970
22.

MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma.

Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, Clarke P, Bosma E, Simbolo M, Scarpa A, Yu S, Cole R, Smyth E, Mateos JF, Begum R, Hezelova B, Eltahir Z, Wotherspoon A, Fotiadis N, Bali MA, Nepal C, Khan K, Stubbs M, Hahne JC, Gasparini P, Guzzardo V, Croce CM, Eccles S, Fassan M, Cunningham D, Andersen JB, Workman P, Valeri N, Braconi C.

Gastroenterology. 2018 Mar;154(4):1066-1079.e5. doi: 10.1053/j.gastro.2017.10.043. Epub 2017 Nov 4.

23.

Phosphoprotein enriched in diabetes (PED/PEA15) promotes migration in hepatocellular carcinoma and confers resistance to sorafenib.

Quintavalle C, Hindupur SK, Quagliata L, Pallante P, Nigro C, Condorelli G, Andersen JB, Tagscherer KE, Roth W, Beguinot F, Heim MH, Ng CKY, Piscuoglio S, Matter MS.

Cell Death Dis. 2017 Oct 26;8(10):e3138. doi: 10.1038/cddis.2017.512.

24.

Differential effects of FXR or TGR5 activation in cholangiocarcinoma progression.

Erice O, Labiano I, Arbelaiz A, Santos-Laso A, Munoz-Garrido P, Jimenez-Agüero R, Olaizola P, Caro-Maldonado A, Martín-Martín N, Carracedo A, Lozano E, Marin JJ, O'Rourke CJ, Andersen JB, Llop J, Gómez-Vallejo V, Padro D, Martin A, Marzioni M, Adorini L, Trauner M, Bujanda L, Perugorria MJ, Banales JM.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1335-1344. doi: 10.1016/j.bbadis.2017.08.016. Epub 2017 Sep 13.

25.

High-Throughput Screening for Compounds that Modulate the Cellular c-di-GMP Level in Bacteria.

Groizeleau J, Andersen JB, Givskov M, Berthelsen J, Tolker-Nielsen T.

Methods Mol Biol. 2017;1657:455-470. doi: 10.1007/978-1-4939-7240-1_33.

PMID:
28889313
26.

A broad range quorum sensing inhibitor working through sRNA inhibition.

Jakobsen TH, Warming AN, Vejborg RM, Moscoso JA, Stegger M, Lorenzen F, Rybtke M, Andersen JB, Petersen R, Andersen PS, Nielsen TE, Tolker-Nielsen T, Filloux A, Ingmer H, Givskov M.

Sci Rep. 2017 Aug 29;7(1):9857. doi: 10.1038/s41598-017-09886-8.

27.

Computer-assisted stereology and automated image analysis for quantification of tumor infiltrating lymphocytes in colon cancer.

Eriksen AC, Andersen JB, Kristensson M, dePont Christensen R, Hansen TF, Kjær-Frifeldt S, Sørensen FB.

Diagn Pathol. 2017 Aug 29;12(1):65. doi: 10.1186/s13000-017-0653-0.

28.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Jun 27;19(13):2878-2880. doi: 10.1016/j.celrep.2017.06.008. No abstract available.

29.

Common Molecular Subtypes Among Asian Hepatocellular Carcinoma and Cholangiocarcinoma.

Chaisaingmongkol J, Budhu A, Dang H, Rabibhadana S, Pupacdi B, Kwon SM, Forgues M, Pomyen Y, Bhudhisawasdi V, Lertprasertsuke N, Chotirosniramit A, Pairojkul C, Auewarakul CU, Sricharunrat T, Phornphutkul K, Sangrajrang S, Cam M, He P, Hewitt SM, Ylaya K, Wu X, Andersen JB, Thorgeirsson SS, Waterfall JJ, Zhu YJ, Walling J, Stevenson HS, Edelman D, Meltzer PS, Loffredo CA, Hama N, Shibata T, Wiltrout RH, Harris CC, Mahidol C, Ruchirawat M, Wang XW; TIGER-LC Consortium.

Cancer Cell. 2017 Jul 10;32(1):57-70.e3. doi: 10.1016/j.ccell.2017.05.009. Epub 2017 Jun 22.

30.

Epigenome dysregulation in cholangiocarcinoma.

O'Rourke CJ, Munoz-Garrido P, Aguayo EL, Andersen JB.

Biochim Biophys Acta Mol Basis Dis. 2018 Apr;1864(4 Pt B):1423-1434. doi: 10.1016/j.bbadis.2017.06.014. Epub 2017 Jun 20. Review.

31.

Transcriptomic and histopathological analysis of cholangiolocellular differentiation trait in intrahepatic cholangiocarcinoma.

Rhee H, Ko JE, Chung T, Jee BA, Kwon SM, Nahm JH, Seok JY, Yoo JE, Choi JS, Thorgeirsson SS, Andersen JB, Lee HS, Woo HG, Park YN.

Liver Int. 2018 Jan;38(1):113-124. doi: 10.1111/liv.13492. Epub 2017 Jul 10.

PMID:
28608943
32.

High mobility group A1 enhances tumorigenicity of human cholangiocarcinoma and confers resistance to therapy.

Quintavalle C, Burmeister K, Piscuoglio S, Quagliata L, Karamitopoulou E, Sepe R, Fusco A, Terracciano LM, Andersen JB, Pallante P, Matter MS.

Mol Carcinog. 2017 Sep;56(9):2146-2157. doi: 10.1002/mc.22671. Epub 2017 May 17.

PMID:
28467612
33.

Association of Aflatoxin and Gallbladder Cancer.

Koshiol J, Gao YT, Dean M, Egner P, Nepal C, Jones K, Wang B, Rashid A, Luo W, Van Dyke AL, Ferreccio C, Malasky M, Shen MC, Zhu B, Andersen JB, Hildesheim A, Hsing AW, Groopman J.

Gastroenterology. 2017 Aug;153(2):488-494.e1. doi: 10.1053/j.gastro.2017.04.005. Epub 2017 Apr 17.

34.

Adverse genomic alterations and stemness features are induced by field cancerization in the microenvironment of hepatocellular carcinomas.

Castven D, Fischer M, Becker D, Heinrich S, Andersen JB, Strand D, Sprinzl MF, Strand S, Czauderna C, Heilmann-Heimbach S, Roessler S, Weinmann A, Wörns MA, Thorgeirsson SS, Galle PR, Matter MS, Lang H, Marquardt JU.

Oncotarget. 2017 Jul 25;8(30):48688-48700. doi: 10.18632/oncotarget.16231.

35.

Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles.

Farshidfar F, Zheng S, Gingras MC, Newton Y, Shih J, Robertson AG, Hinoue T, Hoadley KA, Gibb EA, Roszik J, Covington KR, Wu CC, Shinbrot E, Stransky N, Hegde A, Yang JD, Reznik E, Sadeghi S, Pedamallu CS, Ojesina AI, Hess JM, Auman JT, Rhie SK, Bowlby R, Borad MJ; Cancer Genome Atlas Network, Zhu AX, Stuart JM, Sander C, Akbani R, Cherniack AD, Deshpande V, Mounajjed T, Foo WC, Torbenson MS, Kleiner DE, Laird PW, Wheeler DA, McRee AJ, Bathe OF, Andersen JB, Bardeesy N, Roberts LR, Kwong LN.

Cell Rep. 2017 Mar 14;18(11):2780-2794. doi: 10.1016/j.celrep.2017.02.033. Erratum in: Cell Rep. 2017 Jun 27;19(13):2878-2880.

36.

SOX17 regulates cholangiocyte differentiation and acts as a tumor suppressor in cholangiocarcinoma.

Merino-Azpitarte M, Lozano E, Perugorria MJ, Esparza-Baquer A, Erice O, Santos-Laso Á, O'Rourke CJ, Andersen JB, Jiménez-Agüero R, Lacasta A, D'Amato M, Briz Ó, Jalan-Sakrikar N, Huebert RC, Thelen KM, Gradilone SA, Aransay AM, Lavín JL, Fernández-Barrena MG, Matheu A, Marzioni M, Gores GJ, Bujanda L, Marin JJG, Banales JM.

J Hepatol. 2017 Jul;67(1):72-83. doi: 10.1016/j.jhep.2017.02.017. Epub 2017 Feb 22.

37.

Community maturity to implement Health in All Policies.

Andersen JB, Gulis G.

Int J Public Health. 2017 Jun;62(5):605-612. doi: 10.1007/s00038-017-0951-z. Epub 2017 Feb 21.

PMID:
28224213
38.

An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer.

Vallejo A, Perurena N, Guruceaga E, Mazur PK, Martinez-Canarias S, Zandueta C, Valencia K, Arricibita A, Gwinn D, Sayles LC, Chuang CH, Guembe L, Bailey P, Chang DK, Biankin A, Ponz-Sarvise M, Andersen JB, Khatri P, Bozec A, Sweet-Cordero EA, Sage J, Lecanda F, Vicent S.

Nat Commun. 2017 Feb 21;8:14294. doi: 10.1038/ncomms14294.

39.

Molecular profiling of intrahepatic cholangiocarcinoma: the search for new therapeutic targets.

Oliveira DV, Zhang S, Chen X, Calvisi DF, Andersen JB.

Expert Rev Gastroenterol Hepatol. 2017 Apr;11(4):349-356. doi: 10.1080/17474124.2017.1292127. Epub 2017 Feb 13.

PMID:
28162004
40.

Advances in cholangiocarcinoma research: report from the third Cholangiocarcinoma Foundation Annual Conference.

Abou-Alfa GK, Andersen JB, Chapman W, Choti M, Forbes SJ, Gores GJ, Hong TS, Harding JJ, Vander Heiden MG, Javle M, Kelley RK, Kwong LN, Lowery M, Merrell A, Miyabe K, Rhim A, Saha S, Sia D, Tanasanvimon S, Venook A, Valle JW, Walesky C, Whetstine J, Willenbring H, Zhu AX, Mayer D, Stanger BZ.

J Gastrointest Oncol. 2016 Dec;7(6):819-827. doi: 10.21037/jgo.2016.11.11. No abstract available.

41.

Breaking up Prolonged Sitting does not Alter Postprandial Glycemia in Young, Normal-Weight Men and Women.

Hansen RK, Andersen JB, Vinther AS, Pielmeier U, Larsen RG.

Int J Sports Med. 2016 Dec;37(14):e1. doi: 10.1055/s-0036-1597544. Epub 2016 Dec 22. No abstract available.

PMID:
28008582
42.

Real-Time Monitoring of nfxB Mutant Occurrence and Dynamics in Pseudomonas aeruginosa Biofilm Exposed to Subinhibitory Concentrations of Ciprofloxacin.

Zaborskyte G, Andersen JB, Kragh KN, Ciofu O.

Antimicrob Agents Chemother. 2017 Feb 23;61(3). pii: e02292-16. doi: 10.1128/AAC.02292-16. Print 2017 Mar.

43.

Genetic Optimization of Liver Cancer Therapy: A Patient-Derived Primary Cancer Cell-Based Model.

Munoz-Garrido P, Andersen JB.

Gastroenterology. 2017 Jan;152(1):19-21. doi: 10.1053/j.gastro.2016.11.030. Epub 2016 Nov 23. No abstract available.

PMID:
27888667
44.

Breaking up Prolonged Sitting does not Alter Postprandial Glycemia in Young, Normal-Weight Men and Women.

Hansen RK, Andersen JB, Vinther AS, Pielmeier U, Larsen RG.

Int J Sports Med. 2016 Dec;37(14):1097-1102. doi: 10.1055/s-0042-113466. Epub 2016 Oct 7. Erratum in: Int J Sports Med. 2016 Dec;37(14):e4.

PMID:
27716865
45.

Cholangiocarcinoma stem-like subset shapes tumor-initiating niche by educating associated macrophages.

Raggi C, Correnti M, Sica A, Andersen JB, Cardinale V, Alvaro D, Chiorino G, Forti E, Glaser S, Alpini G, Destro A, Sozio F, Di Tommaso L, Roncalli M, Banales JM, Coulouarn C, Bujanda L, Torzilli G, Invernizzi P.

J Hepatol. 2017 Jan;66(1):102-115. doi: 10.1016/j.jhep.2016.08.012. Epub 2016 Sep 1.

46.

The anti-cancerous drug doxorubicin decreases the c-di-GMP content in Pseudomonas aeruginosa but promotes biofilm formation.

Groizeleau J, Rybtke M, Andersen JB, Berthelsen J, Liu Y, Yang L, Nielsen TE, Kaever V, Givskov M, Tolker-Nielsen T.

Microbiology. 2016 Oct;162(10):1797-1807. doi: 10.1099/mic.0.000354. Epub 2016 Aug 15.

PMID:
27526691
47.

p53-Dependent Nestin Regulation Links Tumor Suppression to Cellular Plasticity in Liver Cancer.

Tschaharganeh DF, Xue W, Calvisi DF, Evert M, Michurina TV, Dow LE, Banito A, Katz SF, Kastenhuber ER, Weissmueller S, Huang CH, Lechel A, Andersen JB, Capper D, Zender L, Longerich T, Enikolopov G, Lowe SW.

Cell. 2016 Jun 2;165(6):1546-1547. doi: 10.1016/j.cell.2016.05.058. No abstract available.

48.

Factors affecting outcome in myasthenia gravis.

Andersen JB, Gilhus NE, Sanders DB.

Muscle Nerve. 2016 Dec;54(6):1041-1049. doi: 10.1002/mus.25205.

PMID:
27251303
49.

Molecular Pathogenesis and Current Therapy in Intrahepatic Cholangiocarcinoma.

Høgdall D, O'Rourke CJ, Taranta A, Oliveira DV, Andersen JB.

Dig Dis. 2016;34(4):440-51. doi: 10.1159/000444562. Epub 2016 May 11. Review.

PMID:
27170400
50.

Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA).

Banales JM, Cardinale V, Carpino G, Marzioni M, Andersen JB, Invernizzi P, Lind GE, Folseraas T, Forbes SJ, Fouassier L, Geier A, Calvisi DF, Mertens JC, Trauner M, Benedetti A, Maroni L, Vaquero J, Macias RI, Raggi C, Perugorria MJ, Gaudio E, Boberg KM, Marin JJ, Alvaro D.

Nat Rev Gastroenterol Hepatol. 2016 May;13(5):261-80. doi: 10.1038/nrgastro.2016.51. Epub 2016 Apr 20.

Supplemental Content

Loading ...
Support Center